Breaking News
August 15, 2018 - New method provides a ‘big picture’ of genetic influences on traits and diseases
August 15, 2018 - Early Onset Type 1 Diabetes Linked to Heart Disease, Shorter Life
August 14, 2018 - SMURF1 provides targeted approach to preventing cocaine addiction relapse
August 14, 2018 - Genetic testing pushed for hereditary high cholesterol disease
August 14, 2018 - Researchers discover new genes involved in Alzheimer’s Disease
August 14, 2018 - Medicare to overhaul ACOs but critics fear fewer participants
August 14, 2018 - Adolescent health projects receive meager percentage of global funding, study finds
August 14, 2018 - University Hospitals Seidman Cancer Center launches new CAR-T therapy trial
August 14, 2018 - In the addiction battle, is forced rehab the solution?
August 14, 2018 - Busting myths about milk – Scope
August 14, 2018 - Platelet-rich plasma does not enhance cartilage formation capabilities of stem cells
August 14, 2018 - Wearable devices and ‘mhealth’ technology emerge as promising tools for better health
August 14, 2018 - Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved Gut Microbiome of Patients with CDI
August 14, 2018 - Cardiac progenitor cells undergo a cell fate switch to build coronary arteries
August 14, 2018 - Study identifies potential guidance to treat gastric cancer patients
August 14, 2018 - Revealed: The molecular mechanism underlying hypertrophic cardiomyopathy, or “workaholic heart”
August 14, 2018 - Diabetes epidemic in Guatemala driven by aging, not obesity
August 14, 2018 - New technology shows potential to streamline the analysis of proteins
August 14, 2018 - Rethinking the stroke rule ‘time is brain’
August 14, 2018 - Incidence of coronary artery compression in children may be more common than previously thought
August 14, 2018 - Study helps to better understand disease caused by Alpha-1 antitrypsin deficiency
August 14, 2018 - AI platform identifies acute neurological illnesses faster than human diagnosis
August 14, 2018 - American College of Rheumatology receives grants to support development of lupus clinical trials
August 14, 2018 - New study explains why women get more migraines than men
August 14, 2018 - American Heart Association Urges Screen Time Limits for Youth
August 14, 2018 - Brief interventions during routine care reduce alcohol use among men with HIV
August 14, 2018 - New genome analysis could identify people at higher risk of common deadly diseases
August 14, 2018 - NIH grant for Mount Sinai to study use of inhaled corticosteroids for treatment of sickle cell disease
August 14, 2018 - Daicel supplies free nanodiamond samples to international researchers
August 14, 2018 - Switching anti-psychotic drugs in first-episode schizophrenia patients does not improve clinical outcomes
August 14, 2018 - Study to examine whether modulating gut bacteria can improve cardiac function in heart failure patients
August 14, 2018 - AI technology could hold key to improving health services
August 14, 2018 - One out of two children not getting enough nutrients needed for their health
August 14, 2018 - Mono-antiplatelet therapy after aortic heart valve replacements may work as well as two drugs
August 14, 2018 - Aid-in-dying patient chooses his last day
August 14, 2018 - Exercise Really Can Chase Away the Blues, to a Point
August 14, 2018 - Surgical mesh implants may cause autoimmune disorders
August 14, 2018 - Researchers develop revolutionary zebrafish model to gain more insight into bone diseases
August 14, 2018 - Researchers discover secret communication hotline between breast cancers and normal cells
August 14, 2018 - Study examines how a person adapts to visual field loss after stroke
August 14, 2018 - Researchers show how specialized nucleic acid-based nanostructures could help target cancer cells
August 14, 2018 - Reducing opioid prescriptions for one operation can also spill over to other procedures
August 14, 2018 - E-cigarettes not so safe but still better than cigarettes
August 14, 2018 - Researchers find link between common ‘harmless’ virus and cardiovascular damage
August 14, 2018 - Initiation of PIMs associated with higher risk of fracture-specific hospitalizations and mortality
August 14, 2018 - Genetically modified mosquitoes and special bed nets help tackle deadly diseases
August 14, 2018 - Advances in treating hep C lead to new option for transplant patients
August 14, 2018 - Study finds quality of doctor-patient discussions about lung cancer screening to be ‘poor’
August 14, 2018 - MSU researchers uncover the effects of aging on regenerative ability of kidneys
August 14, 2018 - Better conditioning, throwing mechanics can help reduce elbow injuries in young baseball pitchers
August 14, 2018 - Brain game doesn’t offer brain gain
August 14, 2018 - Reproductive choices facing women with disabilities require careful consideration
August 14, 2018 - Scientists pinpoint the cause of a rare childhood seizure disorder
August 14, 2018 - Lumpectomy plus radiation associated with reduced risk of breast cancer death, study finds
August 14, 2018 - UAB study shows how ion channel differentiates newborn and mature neurons in the brain
August 14, 2018 - Experts highlight key knowledge gaps that need to be addressed in Ebola vaccine research
August 14, 2018 - Discovery could lead to new drugs against infection and inflammation
August 14, 2018 - Infection Prevention Differs Between Small, Large Hospitals
August 14, 2018 - Mom still matters—In study, young adults tended to prioritize parents over friends
August 14, 2018 - Deep brain stimulation might benefit those with severe alcoholism, preliminary studies show
August 14, 2018 - Study finds increased rate of repeat pregnancies in women with intellectual and developmental disabilities
August 14, 2018 - Lighter sedation fails to reduce risk of postoperative delirium in older patients
August 13, 2018 - Asking better questions about person’s memory could improve doctors’ understanding of patients
August 13, 2018 - U.S. Trauma Doctors Push for Stricter Gun Controls
August 13, 2018 - Asthma and flu: a double whammy
August 13, 2018 - 5 Questions: Donna Zulman on engaging high-need patients in intensive outpatient programs | News Center
August 13, 2018 - Behavioral Nudges Lead to Drop in Prescriptions of Potent Antipsychotic
August 13, 2018 - Potential New Class of Drugs May Reduce Cardiovascular Risk by Targeting Gut Microbes
August 13, 2018 - How to get your kids to eat better
August 13, 2018 - The importance of hearing your patients
August 13, 2018 - Transmission of F. tularensis unlikely to happen through the food chain
August 13, 2018 - Researchers discover epigenetic mechanism underlying ischemic cardiomyopathy
August 13, 2018 - Adolescent health programs receive only a tiny share of international aid, finds research
August 13, 2018 - Fracture risk increases by 30% after gastric bypass, study shows
August 13, 2018 - Quality-improvement project to standardize feeding practices helps micro preemies gain weight
August 13, 2018 - Long-term cannabinoid exposure impairs memory, study shows
August 13, 2018 - New intervention to reduce risk of HIV in young transgender women
August 13, 2018 - Japan human trial tests iPS cell treatment for Parkinson’s
August 13, 2018 - Altered nitrogen metabolism may contribute to emergence of new cancer mutations
August 13, 2018 - Cycling provides greatest health benefits, study finds
Problems Continue To Plague Tumor Biomarker Tests

Problems Continue To Plague Tumor Biomarker Tests

image_pdfDownload PDFimage_print

Action Points

  • Not all tumor biomarker assays regarded as high-quality are highly congruent or have clinical relevance, according to results from two separate comparison studies.
  • Note that while laboratory-developed tests (LDTs) and FDA-approved companion diagnostics (FDA-CDs) both demonstrated a high degree of accuracy and excellent performance using uniform reference materials, results of analyses on non-standard materials show significant variability.

Not all high-quality tumor biomarker assays are highly congruent or have clinical relevance, results from two separate comparison studies showed.

In the first, laboratory-developed tests (LDTs) and FDA-approved companion diagnostics (FDA-CDs) both demonstrated a high degree of accuracy and excellent performance overall for three oncology analytes in College of American Pathologists (CAP) proficiency testing (PT), researchers said.

Pathological evaluation of tumors comparing LDTs and FDA-CDs in 6,897 proficiency responses showed that both test types exceeded 97% accuracy across all comparable molecular oncology proficiency testing samples for BRAF, EGFR, and KRAS genes, according to Annette S. Kim, MD, PhD, of Brigham and Women’s Hospital in Boston, and colleagues.

“These findings support both the excellent and equivalent performance of both LDTs and FDA-CDs in clinical diagnostic testing,” the study authors wrote in JAMA Oncology.

However, a comparison of laboratories’ pre-analytic practices showed more than 60% were using FDA-CDs outside the bounds of FDA-approved methods. Although participants said they made modifications to the FDA-CDs to increase the flexibility of clinical practice, this effectively rendered the assays LDTs, the study authors noted.

“Both FDA-CD and LDT laboratories accept a wide range of specimen preparations, as well as tumor types,” Kim and colleagues said. “Although this flexibility is advantageous for patient care, it is important to recognize that the use of specimens other than formalin-fixed paraffin-embedded samples of the specified tumor type for the FDA-CDs is off-label, resulting in reclassification of the assay as an LDT.”

Laboratories used the assay off-label by accepting specimens with lower tumor content than required for the approved FDA-CD assay, the study revealed. Other practice modifications included accepting unapproved specimen and tumor types, and not quantifying DNA before performing the FDA-CD assay.

In the study, PT responses were included for 2,524 BRAF (14 PT samples), 2,216 EGFR (11 PT samples), and 2,157 KRAS (10 PT samples). Approximately 15% of these assays were performed using commercially available FDA-CD kits and 85% were analyzed as LDTs.

There were no significant differences between LDTs and the FDA-CD acceptability rates for KRAS. The FDA-CDs performed less well than the LDTs for BRAF p.V600K analysis (CD 66.1% versus LDT 88.0%), and the LDT assay was inferior for EGFR p.L861Q mutation (CD 100% versus LDT 91%).

Noting the comparable performance of the two assays, the greater clinical relevance of LDTs and the “significant off-label use of FDA-CDs,” it might make more sense to reclassify FDA-CDs as LTDs, the researchers suggested.

In an accompanying editorial, Daniel F. Hayes, MD, of the University of Michigan Comprehensive Cancer Center, Ann Arbor, noted that a tumor biomarker test that has analytical validity but lacks clinical utility can’t be introduced into routine practice. “Therefore, approval of a tumor biomarker test by the FDA does not necessarily imply that it should be ordered or used to direct patient care,” he said.

In the era of precision oncology medicine, clinicians need to be knowledgeable about tumor biomarkers as well as the tests used to measure them, he added.

Although Hayes called the CAP proficiency testing “terrific” and said it “should make all of us who are clinicians sleep better at night,” he also pointed out that the study included only pathologists participating in the CAP proficiency testing.

“You should hope that your patient’s sample was tested in one of these laboratories and not in one that did not include these proficient pathologists,” he commented.

The number of tested specimens was low, Hayes said, who also zeroed in on the fact that more than half of the laboratories using FDA-CDs didn’t follow manufacturer’s instructions.

“Although it is reassuring that different laboratories using different techniques and assays usually came up with the same results for BRAF, EGFR, and KRAS, these results cannot be extrapolated to other, more complex tumor tests,” he concluded.

Wide Inter-Test Variability

In a related research letter in the same issue, Gonzalo Torga, MD, and Kenneth J. Pienta, MD, of Johns Hopkins University School of Medicine in Baltimore, reported findings from a small study showing very low patient-paired sample congruence between two liquid commercial biopsy tests. Both genetic tests had self-reported high accuracy, specificity, and sensitivity to detect and quantify tumor-specific alteration, and both laboratories were CAP-accredited for cfDNA next-generation sequencing.

However, in 40 patients with metastatic prostate cancer, 6 blood samples were unevaluable. In the remaining 34 samples, complete concordance between the two assays was observed in 9 (35%). The assays were partially concordant in six samples of the remaining 25, but in the last 16 samples, there was no concordance between the assays at all.

“These data cannot determine which test is more accurate but suggest that reported gene alterations will not be the same across different platforms, raising the specter that patients could potentially receive different treatments depending on the cfDNA platform,” the study authors said.

These results are “disturbing,” said Hayes, and have obvious implications for every clinician ordering laboratory-developed tests. Although LTDs have made important contributions to patient care, a lot of uncertainty remains about their accuracy and basis for use, Hayes added.

“I have often said that ‘a bad tumor biomarker test is as bad as a bad drug.’ Caveat emptor is not a good way to practice medicine, and I for one will continue to call for collegial and constructive measures to improve, and in many cases further regulate, tests that are so important for our patients.”

Lead study author Kim reported a relationship with Aushon Biosciences and a number of study co-authors also reported relationships with industry. Second study authors Torga and Pienta disclosed no potential conflicts of interest. Editorialist Hayes reported relationships with OncImmune, Inbiomotion, Merrimack Pharmaceuticals, Eli Lilly Company, Janssen, Menarini/Silicon bioSystems, Puma Biotechnology, Pfizer, AstraZeneca, and Menarini/Silicon bioSystems.

2017-12-19T13:30:00-0500

Tagged with:

About author

Related Articles